Navigation Links
A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations
Date:3/23/2009

WASHINGTON, March 23 /PRNewswire-USNewswire/ -- Since 1993, when the PLCO trial was started, we have awaited the results of this trial with eager anticipation, as have others. The initial report of the results of this study -- and those of a comparable European trial -- published last week in the New England Journal of Medicine have told us two things:

* The studies offer conflicting evidence about the possibility of a prostate cancer-specific survival benefit associated with the regular use of prostate specific antigen (PSA) testing and digital rectal examination (DRE).

* These studies provide no convincing evidence that mass screening of men over 50 or 55 years of age will lead to a prostate cancer-specific survival benefit within 10 years.

We have come together to make two clear statements about these trials:

* Above all we thank the patients, the investigators, and the national authorities that funded these two trials for their efforts. The development and implementation of these trials over the past 16 years has been an enormous commitment by all concerned.

* We enthusiastically support the continued follow-up of patients in the prostate cancer arm of the PLCO study for at least a further 5 years, through 2014, as originally envisaged.

In addition, in the long-term interests of the health of every man in the USA, and with health reform recognized as a national priority, we wish to state the following:

* Every man, regardless of his age, has the right to know whether he is at risk from prostate cancer, a disease that still kills over 28,600 American men every year, and many more around the world. We encourage all men to be proactive, and to seek out information and support in regard to their health.

* We shall continue to encourage every man to discuss his individual risk for prostate cancer with his doctors, and to request the appropriate use of PSA and DRE tests until better options are available. Further clinical action based on results of these tests is also a matter for serious discussion between each patient and his physicians.

* We call upon the federal government to emphasize the need for more research into early detection technologies and methods that will lead to better and more accurate diagnosis of prostate cancer.

* We call upon Congress to increase funding for the Prostate Cancer Research Program at the Department of Defense.

* We call upon the National Institutes of Health to increase funding for prostate cancer research through the National Cancer Institute.

* We call upon the medical research community to place greater emphasis on the development of new clinical tests that can differentiate between those men at greatest need for aggressive prostate cancer treatment and those with indolent forms of the disease who can be well managed without invasive treatment.

This statement is approved by the following U.S.-based prostate cancer advocacy, education, and support organizations:

* Malecare Prostate Cancer Support - www.malecare.com

* Men's Health Network - www.menshealthnetwork.org

* National Alliance of State Prostate Cancer Coalitions - www.naspcc.org

* Prostate Cancer Foundation - www.pcf.org

* Prostate Cancer International - www.pcainternational.org

* Prostate Conditions Education Council - www.prostateconditions.org

* Prostate Health Education Network - www.prostatehealthed.org

* The Prostate Cancer Mission - www.pcmission.org

* The Prostate Net - www.prostatenet.org

* Us TOO International Prostate Cancer Education and Support Network - www.ustoo.com

* Virginia Prostate Cancer Coalition - www.vapcacoalition.org

* Women Against Prostate Cancer - www.womenagainstprostatecancer.org

* ZERO - The Project to End Prostate Cancer - www.zerocancer.org


'/>"/>
SOURCE Men's Health Network
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Octogenarians: Not Too Old for Joint Replacement
2. Beating Blood Clots after Joint Replacement
3. When to Have That Joint Replacement?
4. Orthopaedic Surgeon Shortage Predicted Due to Soaring Joint Replacement Procedures
5. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
6. Texas Back Institute Leads Way in New Facet Joint Clinical Trial
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
9. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
10. Joint Commission Urges Patients to Speak Up About Pain
11. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO), is ... residents. Naloxone is available without ... retail pharmacy, G-3320 Beecher Road. ... Drug Administration, is intended to block or reverse the ... loss of consciousness. The medication is often carried by ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million and ... operations Second-quarter 2017 Branded ... Second-quarter 2017 Sterile Injectables ... Second-quarter 2017 adjusted diluted earnings per ... $0.93 Second-quarter 2017 reported ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... When Amy Cowperthwait left the emergency ... with her a dream to make nursing education more relevant and prepare aspiring nurses ... were integrated into healthcare provider education. , “The human element was missing. ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... for a period of three years for its residential drug and alcohol detox ... given to an organization and shows the organization’s substantial conformance to the CARF ...
(Date:8/17/2017)... ... August 17, 2017 , ... The line-up includes voices ... and effectively grow a dental practice in a competitive market environment where Corporate Dentistry ... that could just transform you and your practice.” says Daniel A. ‘Danny’ Bobrow, AIM ...
(Date:8/17/2017)... ... , ... Elemental LED, a leading U.S. based engineering and technology ... products were honored with Architectural SSL Product Innovation Awards (PIA) for the ... division, Diode LED, provides a wide variety of superior quality linear, task, and accent ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... herself once more by being among Houston’s first plastic surgeons to offer boutique ... plastic surgery care without disrupting busy schedules and maintaining the utmost discretion in ...
Breaking Medicine News(10 mins):